• eGifter

  Participated · Equity · Dec 2013

  eGifter provides an e-gifting platform and consumer-facing mobile website and app that sells more than 225 brands of eGift cards and leverages integrations with social networks. The company was founded in 2011 and is led by CEO Tyler Roye. eGifter is Huntington, NY–based. It raised $3.5M in funding to accelerate growth. The company intends to use the proceeds to add members to its R&D, sales and marketing teams. Backers on the round included follow-on investments from the Long Island Angel Network (LIAN), BDS Capital, Angel Dough Ventures, 94Bits and several angel investors. eGifter provides a hosted social and group gifting platform that can be integrated into retailers’ websites, fan pages and mobile apps, and operates a consumer-facing marketplace on iOS, Android and the web. The platform enables consumers to buy eGift cards from more than 150 major brands and send them with animated eGreeting cards, personalized messages and video. More than a dozen major retailers adopted the solution since its launch in June. The company closed a $1.7M BB angel financing round and has raised nearly $3M in 2013. eGifter intends to use the funds to expand its social gifting platform, is hiring, and aims to raise another round of financing in 2014. GroupGifting.com develops eGifter, a social gifting service that lets consumers purchase eGift cards from major brands and invite Facebook friends to contribute to a group gift. The service is available on Apple iOS, Android and the web. eGifter partners with more than 200 brands and the company has also been described as supporting purchases from over 100 major brands. The company was co-founded in 2011 by Tyler Roye (CEO), Eric Manno (COO), Mark Manno (CFO) and David Levinsky (CTO) and is based in Melville, NY. GroupGifting.com closed an initial angel financing round of undisclosed size led by Bob Brill, and the company is hiring. Early backers named include Andrew Hazen from AngelDough as well as investors Barry Rubenstein, Steve Winick and David Calone.

• Oligomerix

  Participated · Series A · Apr 2012

  Oligomerix is a clinical-stage biotechnology company developing oral small-molecule inhibitors of tau self-association aimed at Alzheimer’s disease and rare tauopathies. Its lead candidate inhibits the beginning of the tau aggregation cascade and has shown efficacy in animal models; preclinical safety studies are complete. The company plans Phase 1a clinical studies to begin in early 3Q 2022 and will use the recent funding to accelerate that transition. A portion of the Series B extension will fund early characterization of multiple second-generation asset series focused on disease modification in dementia. Historically, Oligomerix financed development through non-dilutive NIH-sponsored grants and other small rounds to complete preclinical testing. The company is seeking strategic partners and additional investors to support continued clinical development. Oligomerix focuses on developing disease‑modifying therapeutics for Alzheimer’s disease and related neurodegenerative disorders. The company concentrates on small molecule inhibitors, immunotherapeutic approaches and biomarkers that target tau oligomers and their recently discovered proteolytic enzymatic activity. It intends to use recently raised funds to advance its small molecule inhibitor programs. Oligomerix is led by president and CEO James Moe, Ph.D., MBA, and was founded in 2006. The company is based in New York, located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center. Its current financing activity includes a completed Series B round. Oligomerix develops disease-modifying therapeutics for Alzheimer’s disease and related neurodegenerative disorders. The company focuses on small molecule inhibitors, immunotherapeutic approaches and biomarkers that target tau oligomers and a newly discovered proteolytic enzymatic activity. It is developing a compound-screening assay to identify disease-modifying small molecules and antibody-based therapeutics directed at tau oligomers and their proteolytic activity. Oligomerix intends to use the capital from its recent financing to advance its tau protease inhibitor program, which aims to neutralize tau outside of neurons. Founded in 2006 and led by president and CEO James Moe, Ph.D., MBA, and CSO Eliot Davidowitz, Ph.D., the company is located in the Audubon Biomedical Science and Technology Park at Columbia University Medical Center. The company completed approximately $2M in Series A financing in which new convertible preferred shares were issued and debt was converted.

• Searchandise Commerce

  Participated · Equity · Apr 2010

  Searchandise Commerce operates an online media network for product manufacturers and their retail channel partners. Its service combines paid search with traditional in‑store merchandising practices, enabling manufacturers and their ad agencies to place CPC bids to affect product visibility across a network of retail and comparison shopping sites. The platform aims to help retailers monetize every visitor to their sites, not just those who transact. The company announced a $7 million venture funding round led by Madrona Venture Group and joined by prior backers Cloquet Capital Partners, DFJ Gotham Partners, Draper Associates, Inflection Point Ventures, Milestone Venture Partners and Wheatley Partners. The capital will be used primarily to expand its sales/marketing and operations teams. Brian McAndrews of Madrona led the investment and has joined Searchandise Commerce’s board.

No current team members are available.